Combination gene transfer to potentiate tumor regression

Gene Therapy

Volumn 4, Issue 4, 1997, Pages 361-366

  Ohno, T ^a   Yang, Z ^a   Ling, X ^b   Jaffe, M ^a   Nabel, E G ^b   Normolle, D ^a   Nabel, G J ^a,c  

^a UNIVERSITY OF MICHIGAN   (United States)

^b Department of Internal Medicine ^*  (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Cancer; Gene therapy; MHC; p21

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; EXPRESSION VECTOR; GENE TRANSFER; HISTOCOMPATIBILITY GENE; IMMUNE RESPONSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR REGRESSION; TUMOR VOLUME; VIRUS RECOMBINANT;

EID: 0030947909     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300403     Document Type: Article

References (24)

1. Kern O, Klarnet J, Jensen M, Greenberg PJ. Requirement for recognition of class II MHC molecules and processed antigen for optimal generation of syngeneic tumor specific class I MHC restricted cytotoxic T lymphocytes. J Immunol 1986; 136: 4303-4310.
2. Rosenberg SA, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 1986; 223: 1318-1321
3. Muul LM, Spiess PJ, Director EP, Rosenberg SA. Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma. J Immunol 1987; 138: 989-995.
4. Topalian SL, Solomon D, Rosenberg SA. Tumor-specific cytolysis by lymphocytes infiltrating human melanomas. J Immunol 1989; 142: 3714-3725.
5. Shu S, Rosenberg SA. Adoptive immunotherapy of a newly induced sarcoma: immunologic characteristics of effector cells. J Immunol 1985; 135: 2895-2903.
6. Lafreniere R, Rosenberg SA. Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin 2. Cancer Res 1985; 45: 3735-3741.
7. Rosenberg SA et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. New Engl J Med 1988; 319: 1676-1680.
8. Yoshizawa H, Sakai K, Chang AE, Shu SY. Activation by anti-CD3 of tumor-draining lymph node cells for specific adoptive immunotherapy. Cell Immunol 1991; 134: 473-479.
9. Oldham RK. Natural killer cells: artifact to reality, an odyssey in biology. Cancer Metasi Rev 1983; 2: 323-336.
10. Herberman RB. Multiple functions of natural killer cells, including immunoregulation as well as resistance to tumor growth. Concepts Immunopathol 1985; 1: 96-132.
11. d). Cancer Res 1987; 47: 3136-3140.
12. Pucetti P, Romani L, Fioretti MC. Chemical xenogenization of experimental tumors. Cancer Metast Rev 1987; 6: 93-111.
13. Sugiura C et al. Xenogenization of tumor cells by transfection with plasmid containing env gene of friend leukemia virus. Jpn J Cancer Res 1988; 79: 1259-1263.
14. Tepper RI, Pattengale PK, Leder P. Murine interleukin-4 displays potent antitumor activity in vivo. Cell 1989; 57: 503-512
15. Fearon ER et al. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 1990; 60: 397-403.
16. Gansbacher B et al. Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med 1990; 172: 1217-1224.
17. Gansbacher B et al. Retroviral vector-mediated gamma-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity. Cancer Res 1990; 50: 7820-7825.
18. Esumi N, Hunt B, Itaya T, Frost P. Reduced tumorigenicity of murine tumor cells secreting gamma-interferon is due to non-specific host responses and is unrelated to class I major histocompatibility complex expression. Cancer Res 1991; 51: 1185-1189.
19. Nabel GJ et al. Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans. Proc Natl Acad Sci USA 1993; 90: 11307-11311.
20. Plautz GE et al. Immunotherapy of malignancy by in vivo gene transfer into tumors. Proc Natl Acad Sci USA 1993; 90: 4645-4649.
21. Yang Z et al. The p21 cyclin-dependent kinase inhibitor suppresses tumorigenicity in vivo. Nature Med 1995; 1: 1052-1056.
22. Ohno T et al. Gene therapy for vascular smooth muscle cell proliferation following arterial injury. Science 1994; 265: 781-784.
23. Chen SH et al. Combination gene therapy for liver metastasis of colon carcinoma in vivo. Proc Natl Acad Sci USA 1995; 92: 2577-2581.
24. Sun WH et al. In vivo cytokine gene transfer by gene gun reduces rumor growth in mice. Proc Natl Acad Sci USA 1995; 92: 2889-2893.